Navigation Links
Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
Date:2/8/2008

Clinical Experts To Oversee Phase 3 Program of CGT-2168

MENLO PARK, Calif., Feb. 8 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc., today named a distinguished international panel of medical experts to serve on the Scientific Steering Committee charged with overseeing COGENT, the company's global Phase 3 clinical trial program for its novel combination antiplatelet product CGT-2168.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The panel includes experts in the fields of cardiology, gastroenterology and clinical investigation. "We are extremely pleased that these accomplished clinical scientists will advise us on the COGENT program. Their participation will help ensure its scientific success," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

Members of the COGENT Scientific Steering Committee are:

-- Dr. Deepak Bhatt, Associate Director, Cardiovascular Coordinating

Center, Cleveland Clinic, Cleveland, Ohio

-- Dr. Marc Cohen, Director of the Division of Cardiology, Newark Beth

Israel Medical Center, Newark, New Jersey

-- Dr. Byron Cryer, John C. Vanatta III Professor of Medicine and

Associate Dean for Minority Affairs, Southwestern Medical School,

Dallas, Texas

-- Dr. Angel Lanas, Service of Gastroenterology, University Hospital,

Zaragoza, Spain

-- Dr. Thomas Schnitzer, Professor of Medicine, Division of Rheumatology,

Northwestern University Feinberg School of Medicine, Chicago, Illinois

The Scientific Steering Committee will be responsible for providing scientific and clinical oversight and advice to ensure the data that emerge from the COGENT program are of the highest quality and that the highest level of scientific conduct is maintained.

The ongoing COGENT program will evaluate the efficacy and safety of Cogentus's lead product, CGT-2168, which combines the antiplatelet medicine clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole).

While antiplatelet therapy has been shown to be effective in preventing major cardiovascular events, it is associated with significant gastrointestinal side effects including bleeding, which can interrupt treatment, may require hospitalization or in some cases even result in death. Bleeding from the use of the antiplatelet drugs aspirin and clopidogrel has been shown respectively to be the third and fourth most common causes of U.S. emergency room visits by older adults experiencing adverse drug events.

"It is critical that patients are able to remain on treatment," Dr. Goldsmith said. A new analysis published in this week's Journal of the American Medical Association showed that patients with acute coronary syndrome who stopped taking Plavix nearly doubled their risk of heart attack or death within the first 90 days following the end of treatment.

CGT-2168 is designed to maintain full protective cardiovascular benefits while reducing the potentially serious gastrointestinal side effects commonly associated with antiplatelet therapy. Early results with CGT-2168 show excellent absorption and metabolism of clopidogrel that are unaffected by the delayed-release omeprazole within this combination product. Cogentus believes these findings suggest the novel formulation avoids a drug-drug interaction that has been reported when the individual marketed drugs are co-administered.

"It is important for patients to receive the full cardiovascular effect of dual antiplatelet therapy while reducing gastrointestinal side effects," said Steering Committee member Dr. Marc Cohen. "The COGENT program is evaluating whether CGT-2168 will maintain the cardiovascular benefits of treatment while minimizing bleeding."

"We believe CGT-2168 has the potential to offer an effective yet safer treatment option for the millions of patients who require antiplatelet therapy. With the help of the Scientific Steering Committee, we are committed to a thorough evaluation of the potentially significant benefits of this new medicine," Dr. Goldsmith said.

ABOUT COGENT

COGENT stands for the Clopidogrel and the Optimization of Gastrointestinal Events Trial. The program is expected to enroll more than 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America. The COGENT program is designed to measure the incidence of upper gastrointestinal bleeding and ulcers in patients who take CGT-2168 and aspirin compared with patients who take clopidogrel and aspirin. The vast majority of patients who take clopidogrel also take aspirin.

Physicians and patients interested in obtaining more information about COGENT should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... Grants Pass, OR (PRWEB) , ... February 05, 2016 , ... ... though, with modern technology, such water may be safer than regular municipal or well ... water advocate and radio host Sharon Kleyne, could go a long way toward increasing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its fiscal ... --> --> GAAP results: Revenue ... up $5.1 million or 4.1% from the third quarter ... the fourth quarter of 2014. Revenue for the year ...
Breaking Medicine Technology: